Literature DB >> 18638037

Estimating the size and dynamics of an injecting drug user population and implications for health service coverage: comparison of indirect prevalence estimation methods.

Jo Kimber1, Matthew Hickman, Louisa Degenhardt, Tim Coulson, Ingrid van Beek.   

Abstract

AIMS: (i) To compare indirect estimation methods to obtain mean injecting drug use (IDU) prevalence for a confined geographic location; and (ii) to use these estimates to calculate IDU and injection coverage of a medically supervised injecting facility.
DESIGN: Multiple indirect prevalence estimation methods.
SETTING: Kings Cross, Sydney, Australia. PARTICIPANTS: IDUs residing in Kings Cross area postcodes recorded in surveillance data of the Sydney Medically Supervised Injecting Centre (MSIC) between November 2001 and October 2002. MEASUREMENTS: Two closed and one open capture-recapture (CRC) models (Poisson regression, truncated Poisson and Jolly-Seber, respectively) were fitted to the observed data. Multiplier estimates were derived from opioid overdose mortality data and a cross-sectional survey of needle and syringe programme attendees. MSIC client injection frequency and the number of needles and syringes distributed in the study area were used to estimate injection prevalence and injection coverage.
FINDINGS: From three convergent estimates, the mean estimated size of the IDU population aged 15-54 years was 1103 (range 877-1288), yielding a population prevalence of 3.6% (2.9-4.3%). Mean IDU coverage was 70.7% (range 59.1-86.7%) and the mean adjusted injection coverage was 8.8% (range 7.3-10.8%). Approximately 11.3% of the total IDU population were estimated to be new entrants to the population per month.
CONCLUSIONS: Credible local area IDU prevalence estimates using MSIC surveillance data were obtained. MSIC appears to achieve high coverage of the local IDU population, although only an estimated one in 10 injections occurs at MSIC. Future prevalence estimation efforts should incorporate open models to capture the dynamic nature of IDU populations.

Entities:  

Mesh:

Year:  2008        PMID: 18638037     DOI: 10.1111/j.1360-0443.2008.02276.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  6 in total

1.  Use of Population-Based Surveys for Estimating the Population Size of Persons Who Inject Drugs in the United States.

Authors:  Heather Bradley; Elizabeth M Rosenthal; Meredith A Barranco; Tomoko Udo; Patrick S Sullivan; Eli S Rosenberg
Journal:  J Infect Dis       Date:  2020-09-02       Impact factor: 5.226

2.  Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada.

Authors:  Brendan Jacka; Sarah Larney; Louisa Degenhardt; Naveed Janjua; Stine Høj; Mel Krajden; Jason Grebely; Julie Bruneau
Journal:  Am J Public Health       Date:  2019-11-14       Impact factor: 9.308

3.  Estimates of people who injected drugs within the last 12 months in Belgium based on a capture-recapture and multiplier method.

Authors:  Els Plettinckx; Forrest W Crawford; Jérôme Antoine; Lies Gremeaux; Luk Van Baelen
Journal:  Drug Alcohol Depend       Date:  2020-11-24       Impact factor: 4.492

4.  Illicit and pharmaceutical drug consumption estimated via wastewater analysis. Part B: placing back-calculations in a formal statistical framework.

Authors:  Hayley E Jones; Matthew Hickman; Barbara Kasprzyk-Hordern; Nicky J Welton; David R Baker; A E Ades
Journal:  Sci Total Environ       Date:  2014-03-15       Impact factor: 7.963

5.  Recapture or precapture? Fallibility of standard capture-recapture methods in the presence of referrals between sources.

Authors:  Hayley E Jones; Matthew Hickman; Nicky J Welton; Daniela De Angelis; Ross J Harris; A E Ades
Journal:  Am J Epidemiol       Date:  2014-04-11       Impact factor: 4.897

6.  Improved benchmark-multiplier method to estimate the prevalence of ever-injecting drug use in Belgium, 2000-10.

Authors:  Kaatje Bollaerts; Marc Aerts; Andre Sasse
Journal:  Arch Public Health       Date:  2013-05-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.